ReviewEye (London, England)2017
Protecting retinal ganglion cells.
Review in Eye (London, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- Brain-heart-eye axis revealed by multi-organ imaging genetics and proteomics.Nature biomedical engineering · 2026Article
- CaMKII-based gene therapy protects retinal ganglion cells in a broad range of disease: ischemic retinopathy and congenital glaucoma.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Topical eye treatment with JGRi1, a protein/protein interaction inhibitor, mitigates retinal degeneration.Cell death & disease · 2026Article
- Analysis of the correlation between mental status and ocular and systemic indicators in patients with primary angle-closure glaucoma.BMC ophthalmology · 2025Article
- Childhood or adolescent abuse and primary open-angle glaucoma in a longitudinal cohort of women.Eye (London, England) · 2025Article
- SVM-Based Optical Detection of Retinal Ganglion Cell Apoptosis.Photonics · 2025Article
- Ouabain Counteracts Retinal Ganglion Cell Death Through Modulation of BDNF and IL-1 Signaling Pathways.Brain sciences · 2025Article
- Periodontitis Provokes Retinal Neurodegenerative Effects of Metabolic Syndrome: A Cross-Sectional Study.Dentistry journal · 2024Article
- Circular RNA-based therapy provides sustained and robust neuroprotection for retinal ganglion cells.Molecular therapy. Nucleic acids · 2024Article
- TREM2-dependent activation of microglial cell protects photoreceptor cell during retinal degeneration via PPARγ and CD36.Cell death & disease · 2024Article
- Antioxidant effect of gallic acid on retinal ganglion cells in glaucoma model.Scientific reports · 2024Article
- Navigating the intersection of psychiatry and ophthalmology: A comprehensive review of depression and anxiety management in glaucoma patients.World journal of psychiatry · 2024Review
- A study exploring the causal relationship between glaucoma and anxiety disorders.Frontiers in medicine · 2024Article
- Recent Advances of Ocular Drug Delivery Systems: Prominence of Ocular Implants for Chronic Eye Diseases.Pharmaceutics · 2023Review
- The Role of Nrf2/sMAF Signalling in Retina Ageing and Retinal Diseases.Biomedicines · 2023Review
- Intravitreal Injection of AAV for the Transduction of Mouse Retinal Ganglion Cells.Methods in molecular biology (Clifton, N.J.) · 2023Article
- σScientific reports · 2022Article
- Visual Field Endpoints for Neuroprotective Trials: A Case for AI-Driven Patient Enrichment.American journal of ophthalmology · 2022Article
- A novel viewpoint in glaucoma therapeutics: enriched environment.Neural regeneration research · 2022Review
- Electrical neurostimulation in glaucoma with progressive vision loss.Bioelectronic medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Retinal ganglion cell degeneration underlies several conditions which give rise to significant visual compromise, including glaucoma, hereditary optic neuropathies, ischaemic optic neuropathies, and demyelinating disease. In this review, we discuss the emerging strategies for neuroprotection specifically in the context of glaucoma, including pharmacological neuroprotection, mesenchymal stem cells, and gene therapy approaches. We highlight potential pitfalls that need to be considered when developing these strategies and outline future directions, including the prospects for clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.